Table 2.

Relative risks of CHD by quintiles of apoE content in LDL, VLDL, or VLDL+LDL with apoC‐III

	Relative Risk for Q5 vs Q1	P Value for Trend
apoE:apoB molar ratio in VLDL with apoC‐III
Model 1	0.50 (0.35 to 0.72)	<0.001
Model 2	0.48 (0.32 to 0.72)	0.002
Model 3	0.52 (0.34 to 0.79)	0.005
Model 3+plasma LDL cholesterol	0.61 (0.40 to 0.94)	0.040
Model 3+plasma HDL cholesterol	0.61 (0.40 to 0.94)	0.048
Model 3+plasma triglycerides	0.60 (0.39 to 0.92)	0.030
Model 3+plasma C‐reactive protein	0.51 (0.34 to 0.78)	0.005
apoE:apoB molar ratio in LDL with apoC‐III
Model 1	0.45 (0.31 to 0.64)	<0.001
Model 2	0.47 (0.32 to 0.70)	<0.001
Model 3	0.53 (0.35 to 0.80)	0.002
Model 3+plasma LDL cholesterol	0.64 (0.42 to 0.97)	0.041
Model 3+plasma HDL cholesterol	0.65 (0.43 to 1.00)	0.038
Model 3+plasma triglycerides	0.69 (0.44 to 1.08)	0.09
Model 3+plasma C‐reactive protein	0.53 (0.35 to 0.80)	0.002
apoE:apoB molar ratio in VLDL+LDL with apoC‐III
Model 1	0.43 (0.30 to 0.62)	<0.001
Model 2	0.48 (0.32 to 0.71)	<0.001
Model 3	0.53 (0.35 to 0.79)	0.002
Model 3+plasma LDL cholesterol	0.63 (0.41 to 0.96)	0.05
Model 3+plasma HDL cholesterol	0.60 (0.40 to 0.90)	0.018
Model 3+plasma triglycerides	0.63 (0.41 to 0.95)	0.034
Model 3+plasma C‐reactive protein	0.50 (0.33 to 0.75)	0.001

Model 1 is conditioned on matching factors only; model 2 is additionally adjusted for parental history of CHD before the age of 60 years, alcohol intake, and history of hypertension at baseline. Model 3 is adjusted for everything in model 2 plus body mass index and history of diabetes at baseline. Relative risks and 95% CIs are given for the highest quintile compared with the lowest quintile of each variable. CHD indicates coronary heart disease; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; VLDL, very‐low‐density lipoprotein; apoE, apolipoprotein E; apoB, apolipoprotein B; apoC‐III, apolipoprotein C‐III; Q, quintile.